Mexitil and Rash for Women aged 60+ (a phase IV clinical study of FDA data)

Summary:

Rash is found for women aged 60+ who take Mexitil (mexiletine hydrochloride). This study is created by eHealthMe based on reports of 435 women aged 60+ from the FDA, and is updated regularly. The information that eHealthMe analyzes includes:

Time on Mexitil when people have Rash
Top conditions
Top co-used drugs
Top other side effects

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Jul, 05, 2026

435 women aged 60+ reported to have side effects when taking Mexitil.
Among them, 43 people (9.89%) have Rash

What is Mexitil?

Mexitil has active ingredients of mexiletine hydrochloride. eHealthMe is studying from 1,893 Mexitil users. Check the latest studies of Mexitil.

What is Rash?

Rash is found to be associated with 3,971 drugs and 6,221 conditions by eHealthMe. Check the latest studies of Rash.

Number of reports submitted per year:

Could Mexitil cause Rash in women aged 60+?

Time on Mexitil when people have Rash *

Severity of Rash

n/a

How people recovered from Rash

n/a

Top conditions involved for these people *:

You may use this to check any potential undetected conditions.

Ventricular Extrasystoles (premature cardiac contraction): 10 people, 23.26%
High Blood Pressure: 8 people, 18.60%
Arrhythmias (irregular heartbeat): 6 people, 13.95%
Cancer Pain: 4 people, 9.30%
Pleural Mesothelioma Malignant (cancer of the pleura, or the membrane that lines the lungs): 4 people, 9.30%
Chest Pain: 4 people, 9.30%
Hyperlipidaemia (presence of excess lipids in the blood): 3 people, 6.98%
Pain: 3 people, 6.98%
Nasopharyngitis (inflammation of the nasopharynx): 2 people, 4.65%
Constipation: 2 people, 4.65%

Top co-used drugs for these people *:

You may use this to check any potential interacting drugs.

Top other side effects for these people *:

You may use this to check any potential undetected side effects.

Itching: 9 people, 20.93%
Fever: 8 people, 18.60%
Drug Hypersensitivity: 7 people, 16.28%
Skin Erosion (a discontinuity of the skin): 5 people, 11.63%
Hepatic Function Abnormal: 5 people, 11.63%
Antibody Test Positive: 5 people, 11.63%
Lymphocyte Stimulation Test Positive: 5 people, 11.63%
Pemphigus (any of several acute or chronic skin diseases characterized by groups of itching blisters): 5 people, 11.63%
Hepatocellular Damage (liver damage): 4 people, 9.30%
Eosinophil Count Increased: 4 people, 9.30%

* Approximation only. Some reports may have incomplete information.

Do you take Mexitil and have Rash?

- Check whether Rash is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Related publications that referenced our studies:

Mohammad MM, Syrigos KN, Saif MW, "Association between Rash and a Positive Drug Response Associated with Vinorelbine in a Patient with Primary Peritoneal Carcinoma", Case reports in dermatological medicine, 2013 Sep .
Mohammad MM, Syrigos KN, Saif MW, "Association between Rash and a Positive Drug Response Associated with Vinorelbine in a Patient with Primary Peritoneal Carcinoma", Case reports in dermatological medicine, 2013 Sep .

Related studies:

Mexitil and Rash

How the study uses the data?

The study is based on (applicable) gender, age, mexiletine hydrochloride (the active ingredients of Mexitil) and Mexitil (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.